Another FDA approved (2007) HER-targeting drug for metastatic cancer is lapatinib, a kinase inhibitor of both the epidermal growth factor receptor (EGFR) and HER2 [47] (Fig. 2). This evidence concerns the gene EGFR and metastatic malignant neoplasm.